CNN Central News & Network-ITDC India Epress/ITDC News Bhopal: In Nagpur, some batches of paracetamol 500 mg and the blood pressure medicine Telmisartan 40 mg failed to meet quality standards in an investigation by the Maharashtra Food and Drug Administration (FDA). Following this, government hospitals have been directed to stop distributing these medicines and recall the related stock.
According to the report, the affected medicines had been supplied to Nagpur’s Government Medical College and Hospital (GMCH) and Indira Gandhi Government Medical College and Hospital, also known as Mayo Hospital. The FDA had collected samples of the medicines from Mayo Hospital in August. In the test report issued on September 10, both medicines were found not to conform to the prescribed quality standards.
In the Parasev 500 batch PTTC-108, spots on the tablets and slight variation in colour were found. In Telmisartan 40 mg batch CHPLT 416, a deficiency was found in the dissolution test. This test checks how quickly and in what quantity a medicine dissolves for absorption in the body.
According to the report, both medicines were manufactured by Indore-based Cureza Healthcare Private Ltd. The FDA has started checking the supply of the relevant batches and the available stock. For now, distribution of the affected batches in hospitals has been stopped. Monitoring drug quality in India is the responsibility of central and state drug regulatory bodies. The objective of CDSCO is to ensure the safety, effectiveness and quality of medicines available in the market.
Hashtags: #Health #Bhopal #Nagpur #MaharashtraFDA #Paracetamol #Telmisartan #DeskSource #Paracetamol500Mg #Telmisartan40Mg #GMCH
